Life science and healthcare specialists – AMSBIO has launched a new set of dedicated webpages and content downloads detailing their extensive range of high quality GMP-compliant products and services.
Good Manufacturing Practice (GMP) is an internationally recognized system which ensures that products are consistently manufactured to a high-quality and provides key guidelines for the manufacture of Advanced Therapy Medicinal Products (ATMPs). Operating as an ISO 9001 registered organization - AMSBIO understand the importance of offering GMP compliant products and services with guaranteed…
WESTBROOK, Connecticut (USA) - The Lee Company is pleased to announce that it has acquired TTP Ventus Limited from TTP Group. Based near Cambridge, UK, TTP Ventus is an inventor and manufacturer of silent, compact micropumps and pump modules with unrivalled features, enabling cutting-edge innovation across the medical, life science, environmental, and industrial sectors. These products complement The Lee Company’s existing broad range of miniature fluid control components widely utilized across the same industries.
“TTP Ventus brings exciting new technology to The Lee Company, enhancing our…
XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, based in Japan. XenoTech specializes in ADME, DMPK and DDI testing of potential drug candidates.
This transaction demonstrates BioIVT’s continuing commitment to…
Macomics Announces the Appointment of Roche Executive, Dr Valérie Méresse Naegelen, to its Clinical Advisory Panel
Edinburgh and Cambridge, UK, 12 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen, Global Head of Translational Sciences Oncology at the Pharma Division of Roche has joined its panel of Clinical Advisors.
Dr Méresse Naegelen has over 20 years of experience in research and clinical development of small and large molecule compounds for various indications in oncology…
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.
“We are looking forward to meeting with the research community at ISSX,” said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. “The ISSX conference is an important event in our year,…
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes
Cambridge, UK, 06 September 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.
PhoreMost will…
Press release
Macomics to Present at Upcoming Conferences, Q3 2022
Edinburgh and Cambridge, UK, 1 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
• Dr Luca Cassetta, co-founder and VP Immunology of Macomics will be attending the 2022 ISEH Annual meeting, Edinburgh, 1-4 September
o Speaking at Q&A session on transition from academia to start up, 2 September
• Dr Steve Myatt, CEO of Macomics, will be…
AMSBIO has published an interview with Professor Marius Wernig from Stanford University, Pathology Stem Cell Institute that discusses what could be the world’s first widely applicable curative treatment for Epidermolysis Bullosa (EB).
This rare genetic disease causes chronic and incredibly painful skin wounds that often lead to an aggressive form of skin cancer and eventual death.
While various cell-therapy approaches have been attempted, Professor Wernig and collaborators identified the need for induced pluripotent stem cells (iPSCs), and how they could become used to treat EB in a more…
The next wave of talent “…are looking for destination locations that align with the values and ethos of the company and often the physical structure that’s in to enable innovation is part of what attracts the best people” Tony Jones, One Nucleus.
Listen to the full podcast with Chris Walters, JLL’s Head of UK Life Sciences and Tony Jones, CEO of One Nucleus where they discussed the importance of destination locations for innovation in life sciences. They covered a range of topics affecting the life sciences sector in the UK including, how destination real estate locations can enable…